恢复期血浆联合标准治疗住院COVID-19患者的随机多中心II期概念验证试验
DAWn-Plasma是一项在比利时25个中心开展的随机、开放标签、II期概念验证试验,计划纳入483例住院COVID-19患者,按2:1随机接受标准治疗联合恢复期血浆或仅标准治疗。主要终点为第15天需要机械通气或死亡的患者比例,旨在评估恢复期血浆添加至标准治疗的临床疗效与安全性。
要点
- 住院COVID-19患者在症状出现且72小时内经PCR或胸部CT确诊后符合入选标准。
- 恢复期血浆组在随机后12小时内输注2单位200-250 mL血浆,24-36小时后再次输注2单位。
- 主要终点为第15天机械通气或死亡比例,关键次要终点包括第15天和第30天WHO 10点序贯量表临床状态及安全性。
核心结论
- 该试验将提供支持或不鼓励使用恢复期血浆作为住院COVID-19患者早期干预措施的证据。
研究设计与样本
- 多中心、全国性、随机、开放标签、II期概念验证临床试验,在比利时25个中心招募,计划纳入483例住院COVID-19患者。
- 患者按2:1比例随机分配至标准治疗联合恢复期血浆组或仅标准治疗组。
关键数值与推荐
- 入选标准:确诊COVID-19且有症状(临床或影像学征象),并在研究纳入前72小时内经PCR(鼻/鼻咽拭子或支气管肺泡灌洗)或胸部CT显示与COVID-19 compatible features且无其他替代诊断。
- 主动治疗组在随机后12小时内接受2单位200至250 mL恢复期血浆,首次输注结束后24至36小时再次给予2单位。
- 主要终点:第15天需要机械通气或死亡的患者比例。
- 主要次要终点:随机后第15天和第30天根据WHO Progression 10点序贯量表定义的临床状态,以及恢复期血浆给药的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The COVID-19 pandemic has imposed an enormous burden on health care systems around the world. In the past, the administration of convalescent plasma of patients having recovered from SARS and severe influenza to patients actively having the disease showed promising effects on mortality and appeared safe. Whether or not this also holds true for the novel SARS-CoV-2 virus is currently unknown. METHODS: DAWn-Plasma is a multicentre nation-wide, randomized, open-label, phase II proof-of-concept clinical trial, evaluating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19 in Belgium. Patients hospitalized with a confirmed diagnosis of COVID-19 are eligible when they are symptomatic (i.e. clinical or radiological signs) and have been diagnosed with COVID-19 in the 72 h before study inclusion through a PCR (nasal/nasopharyngeal swab or bronchoalveolar lavage) or a chest-CT scan showing features compatible with COVID-19 in the absence of an alternative diagnosis. Patients are randomized in a 2:1 ratio to either standard of care and convalescent plasma (active treatment group) or standard of care only. The active treatment group receives 2 units of 200 to 250 mL of convalescent plasma within 12 h after randomization, with a second administration of 2 units 24 to 36 h after ending the first administration. The trial aims to include 483 patients and will recruit from 25 centres across Belgium. The primary endpoint is the proportion of patients that require mechanical ventilation or have died at day 15. The main secondary endpoints are clinical status on day 15 and day 30 after randomization, as defined by the WHO Progression 10-point ordinal scale, and safety of the administration of convalescent plasma. DISCUSSION: This trial will either provide support or discourage the use of convalescent plasma as an early intervention for the treatment of hospitalized patients with COVID-19 infection. TRIAL REGISTRATION: ClinicalTrials.gov NCT04429854 . Registered on 12 June 2020 - Retrospectively registered.
引用
- Devos T, Geukens T, Schauwvlieghe A, et al. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials. 2020. PMID: 33246499. doi:10.1186/s13063-020-04876-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。